LyondellBasell: The Market Ignores A Massive Earnings Recovery

LyondellBasell reiteration as a Buy around ~$63 follows Q2 results that far exceeded expectations, led by O&P Americas with adjusted EBITDA up to $1.27B. The article flags that these elevated margins likely won’t persist as Middle East supply normalizes, but highlights structural upside from cost cutting, asset sales, and a stronger balance sheet with net debt/EBITDA down to 2.6x. Overall, the setup is positive on durability of profitability even at normalized margins.

Analysis

The key market mechanism is not the quarter itself but the mix of peak margin optics versus self-help. LYB’s earnings power is still heavily exposed to olefins/polyolefins spreads, so if Middle East supply normalizes, consensus EBITDA will likely mean-revert faster than the stock will. That makes the next 1-3 months about estimate revisions: if pricing rolls while volume stays stable, the market will start discounting normalized free cash flow rather than headline quarterly beats.

The more durable upside is balance-sheet optionality. Moving net debt/EBITDA toward the mid-2s materially increases equity duration because every dollar of incremental cash flow can shift from debt reduction to buybacks or bolt-on portfolio moves; that matters more for LYB than for more levered peers like DOW. Second-order, lower leverage should also compress the company’s cost of equity and support a higher trough multiple even if margins normalize, which reduces downside versus names whose equity is still hostage to credit perception.

Contrarian view: the market may be over-fixated on whether the current margin is peak, and underestimating that a cleaner balance sheet and asset rationalization can raise normalized earnings quality. Falsifiers are simple: sustained ethylene spreads above historical mid-cycle levels for another 2-3 quarters, or management guidance that shows the cost cuts are permanently offsetting price normalization. If instead spreads revert quickly, the stock likely trades back on trough EV/EBITDA and the recent outperformance fades.

Key Decisions for Investors

• Long LYB on weakness, but treat it as a normalized-earnings compounder rather than a cyclical breakout; best entry is on any post-earnings fade if the market starts pricing peak-margin compression.
• Pair trade: long LYB / short DOW over 1-3 months. LYB has better balance-sheet repair and cleaner self-help, while DOW’s equity remains more sensitive to spread normalization and leverage risk.
• Use LYB as a watchlist long for 6-18 months only if management continues deleveraging faster than expected; the thesis breaks if net debt/EBITDA stalls above ~3x or buyback capacity is deferred.
• No aggressive option call here unless you have a strong view on sustained spreads; the cleaner trade is equity or pair exposure, since the main risk is valuation compression from normalization rather than a binary event.